Patents by Inventor Gerard B. Fox

Gerard B. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF
    Publication number: 20170002075
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Application
    Filed: July 18, 2016
    Publication date: January 5, 2017
    Inventors: Jijie GU, Chung-Ming HSIEH, Zhen WU, Enrico L. DiGIAMMARINO, Feng LUO, Gerard B. FOX, John E. HARLAN, Martin SCHMIDT, Ralf LOEBBERT, Reinhold MUELLER, Ulrich EBERT, Volker NIMMRICH
  • Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
    Patent number: 9394363
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: July 19, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Jijie Gu, Chung-Ming Hsieh, Zhen Wu, Enrico L. DiGiammarino, Feng Luo, Gerard B. Fox, John E. Harlan, Martin Schmidt, Ralf Loebbert, Reinhold Mueller, Ulrich Ebert, Volker Nimmrich
  • Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
    Patent number: 8323651
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid ? and advanced glycation-end-products.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: December 4, 2012
    Assignees: Abbott Laboratories, Abbott GmbH & Co. KG
    Inventors: Jijie Gu, Chung-Ming Hsieh, Zhen Wu, Enrico L. DiGiammarino, Feng Luo, Gerard B. Fox, John E. Harlan, Martin Schmidt, Ralf Loebbert, Reinhold Mueller, Ulrich Ebert, Volker Nimmrich
  • Treatment of schizophrenia and related disorders
    Patent number: 8252801
    Abstract: The invention relates to a method of administering histamine H3 antagonist and an antipsychotic therapeutic agent, compositions comprising a histamine H3 antagonist and an antipsychotic therapeutic agent, and a related article of manufacture.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 28, 2012
    Assignee: Abbott Laboratories
    Inventors: Lynne E. Rueter, Kaitlin E. Browman, Jorge D. Brioni, Marlon D. Cowart, Timothy A. Esbenshade, Gerard B. Fox
  • ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF
    Publication number: 20100028359
    Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example misfolded proteins like amyloid B and advanced glycation-end-products.
    Type: Application
    Filed: May 8, 2009
    Publication date: February 4, 2010
    Applicants: ABBOTT GMBH & CO. KG, ABBOTT LABORATORIES
    Inventors: Jijie GU, Chung-Ming HSIEH, Zhen WU, Enrico L. DiGIAMMARINO, Feng LUO, Gerard B. FOX, John E. HARLAN, Martin SCHMIDT, Ralf LOEBBERT, Reinhold MUELLER, Ulrich EBERT, Volker NIMMRICH